Synopsis: Glenmark Pharmaceuticals has launched Winlevi® (clascoterone 10 mg/g cream) across key European markets for the treatment of acne vulgaris. The launch marks Glenmark’s first New Chemical Entity (NCE) launch in Europe and strengthens its dermatology portfolio across the region.
Shares of Glenmark Pharmaceuticals Limited are likely to remain in focus after the company announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key European markets, marking a significant milestone in its specialty dermatology business.
Glenmark Pharmaceuticals Limited has a total market capitalization of approximately Rs. 60,966.66 crore. The company’s shares were trading at Rs. 2160.10 apiece on the stock exchange, up by 0.73 percent during the session. The stock has declined around 0.93 percent over the last five trading sessions. The stock has declined around 7.96 percent over the last month, reflecting negative momentum. The stock touched a 52-week high of Rs. 2474 and a 52-week low of Rs. 1589.
Glenmark Pharmaceuticals Limited has a global presence across generics, specialty pharmaceuticals, and OTC products, with operations spanning more than 80 countries. The latest launch is expected to strengthen the company’s branded dermatology portfolio in Europe while expanding access to innovative treatments.
According to the company’s press release, the launch has been undertaken through Glenmark Specialty S.A. (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals. The product has been introduced across several European markets, including the Nordics, Central and Eastern Europe, and Spain, while launches in Portugal and other regions are being pursued through strategic partnerships.
The launch follows the European Commission’s approval granted in October 2025 to Cassiopea S.p.A., a subsidiary of Cosmo N.V., for the treatment of acne vulgaris in adults and adolescents aged 12 to below 18 years.
Winlevi® is considered a significant innovation in dermatology as it is the first topical acne treatment introduced in more than 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor that acts locally within sebaceous glands to reduce sebum production and inflammation without causing systemic anti-androgen effects.
The launch is particularly important given the widespread prevalence of acne. Industry estimates indicate that more than 95 percent of males and 85 percent of females experience acne during adolescence, while nearly half continue to face the condition into adulthood. Acne can significantly affect both physical appearance and psychological well-being, making effective treatment options an important area of demand within dermatology.
Glenmark stated that the launch reflects its continued focus on bringing differentiated therapies to patients and healthcare professionals across global markets. The company plans to leverage a combination of direct commercial presence and strategic partnerships to expand the product’s reach across Europe.
Commenting on the development, Jiri Havranek, Group Vice President and Business Head – Europe at Glenmark Pharmaceuticals, said the launch represents an important step in strengthening the company’s dermatology portfolio and branded business in the region. He added that it demonstrates Glenmark’s ability to successfully execute multi-market launches while expanding access to innovative therapies.
The development also supports Glenmark’s broader strategy of increasing its presence in specialty pharmaceuticals, where differentiated products generally offer higher margins and stronger brand recognition compared to traditional generic medicines.
Incorporated as a global research-led pharmaceutical company, Glenmark Pharmaceuticals operates across branded formulations, specialty products, generics, and consumer healthcare segments. The company maintains 11 manufacturing facilities and six R&D centers worldwide and focuses on therapeutic areas including respiratory, dermatology, and oncology.
The launch of Winlevi® not only marks Glenmark’s first NCE launch in Europe but also strengthens its position in the global dermatology market, potentially opening new growth opportunities in specialty pharmaceuticals across the region.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
